MicroRNA‑885‑5p regulates cell cycle progression in liver cancer cells

Ariyachet,Chaiyaboot; Nokkeaw,Archittapon; Tangkijvanich,Pisit

doi:10.3892/ijmm.2025.5608

MicroRNA‑885‑5p regulates cell cycle progression in liver cancer cells

Authors:
- Chaiyaboot Ariyachet
- Archittapon Nokkeaw
- Pisit Tangkijvanich
View Affiliations

Affiliations: Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
Published online on: August 12, 2025 https://doi.org/10.3892/ijmm.2025.5608
Article Number: 167
Copyright: © Ariyachet et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are small non‑coding RNAs that regulate gene expression by targeting messenger RNAs for translational repression or degradation. Dysregulation of miRNAs has been implicated in liver cancer development, including hepatocellular carcinoma (HCC). The present study identified miR‑885‑5p as a novel tumor-suppressor miRNA in liver cancer. Analysis of miRNA expression profiles from The Cancer Genome Atlas Program and Gene Expression Omnibus databases demonstrated a consistent downregulation of miR‑885‑5p in HCC tissues. Overexpression of miR‑885‑5p via lentiviral transduction significantly suppressed liver cancer cell proliferation, supporting its tumor‑suppressive role. To investigate the underlying mechanism, transcriptomic profiling of miR‑885‑5p‑overexpressing liver cancer cells was performed. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analyses highlighted the cell cycle as the most significantly affected pathway. Specifically, miR‑885‑5p downregulated key G₁/S transition‑promoting genes, including CDK6, E2F Transcription Factor 2 and Origin Recognition Complex Subunit 1 (ORC1), in liver cancer cells. To examine if miR‑885‑5p regulates the G1/S transition, a bromodeoxyuridine labeling assay and cell cycle analysis were performed. Corroborating the transcriptomic data, liver cancer cells with overexpressed miR‑885‑5p exhibited reduced bromodeoxyuridine incorporation and G₁ phase arrest. To gain further mechanistic insights, bioinformatics tools were used to predict gene targets of miR‑885‑5p in the G₁/S transition. Dual luciferase assays were conducted, which identified the direct interaction of miR‑885‑5p with the 3' untranslated regions of CDK6 and ORC1 messenger RNAs. Given its inhibitory effect on the G₁/S transition, the therapeutic potential of miR‑885‑5p was assessed. miR‑885‑5p overexpression sensitized liver cancer cells to the CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib. The present findings collectively demonstrated that miR‑885‑5p induces cell cycle arrest and enhances CDK4/6 inhibitor sensitivity in liver cancer, suggesting its potential as a therapeutic target.

View Figures

View References

1	Petrick JL and McGlynn KA: The changing epidemiology of primary liver cancer. Curr Epidemiol Rep. 6:104–111. 2019. View Article : Google Scholar : PubMed/NCBI
2	Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI
3	Vitale A, Trevisani F, Farinati F and Cillo U: Treatment of hepatocellular carcinoma in the precision medicine era: From treatment stage migration to therapeutic hierarchy. Hepatology. 72:2206–2218. 2020. View Article : Google Scholar : PubMed/NCBI
4	Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP and Lurje G: Treatment strategies for hepatocellular carcinoma-a multidisciplinary approach. Int J Mol Sci. 20:14652019. View Article : Google Scholar
5	Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS: Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 19:151–172. 2022. View Article : Google Scholar
6	Yang JD and Heimbach JK: New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 371:m35442020. View Article : Google Scholar : PubMed/NCBI
7	ENCODE Project Consortium; Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, et al: Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 447:799–816. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bushati N and Cohen SM: microRNA functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ma N, Tan J, Chen Y, Yang L, Li M and He Y: MicroRNAs in metabolic dysfunction-associated diseases: Pathogenesis and therapeutic opportunities. FASEB J. 38:e700382024. View Article : Google Scholar : PubMed/NCBI
10	Mansour RM, Abdel Mageed SS, Abulsoud AI, Sayed GA, Lutfy RH, Awad FA, Sadek MM, Shaker AAS, Mohammed OA, Abdel-Reheim MA, et al: From fatty liver to fibrosis: The impact of miRNAs on NAFLD and NASH. Funct Integr Genomics. 25:302025. View Article : Google Scholar : PubMed/NCBI
11	Rahdan F, Saberi A, Saraygord-Afshari N, Hadizadeh M, Fayeghi T, Ghanbari E, Dianat-Moghadam H and Alizadeh E: Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights. Heliyon. 10:e394892024. View Article : Google Scholar : PubMed/NCBI
12	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
13	Diener C, Keller A and Meese E: Emerging concepts of miRNA therapeutics: From cells to clinic. Trends Genet. 38:613–626. 2022. View Article : Google Scholar : PubMed/NCBI
14	Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al: Treatment of HCV infection by targeting microRNA. N Engl J Med. 368:1685–1694. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hong DS, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 122:1630–1637. 2020. View Article : Google Scholar : PubMed/NCBI
16	Di Martino MT, Tagliaferri P and Tassone P: MicroRNA in cancer therapy: Breakthroughs and challenges in early clinical applications. J Exp Clin Cancer Res. 44:1262025. View Article : Google Scholar
17	Sareen G, Mohan M, Mannan A, Dua K and Singh TG: A new era of cancer immunotherapy: Vaccines and miRNAs. Cancer Immunol Immunother. 74:1632025. View Article : Google Scholar : PubMed/NCBI
18	Wang F, Zuroske T and Watts JK: RNA therapeutics on the rise. Nat Rev Drug Discov. 19:441–442. 2020. View Article : Google Scholar : PubMed/NCBI
19	Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI and Cooke JP: The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 9:6281372021. View Article : Google Scholar : PubMed/NCBI
20	Kingston RE, Chen CA and Rose JK: Calcium phosphate transfection. Curr Protoc Mol Biol. 63:9.1.1–9.1.11. 2003. View Article : Google Scholar
21	Anastasov N, Höfig I, Mall S, Krackhardt AM and Thirion C: Optimized lentiviral transduction protocols by use of a poloxamer enhancer spinoculation, and scFv-antibody fusions to VSV-G. Lentiviral Vectors and Exosomes as Gene and Protein Delivery Tools. Federico M: Springer New York; New York, NY: pp. 49–61. 2016, View Article : Google Scholar
22	Mei Q, Li X, Meng Y, Wu Z, Guo M, Zhao Y, Fu X and Han W: A facile and specific assay for quantifying microRNA by an optimized RT-qPCR approach. PLoS One. 7:e468902012. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Xu F, Wang Y, Ling Y, Zhou C, Wang H, Teschendorff AE, Zhao Y, Zhao H, He Y, Zhang G and Yang Z: dbDEMC 3.0: Functional exploration of differentially expressed miRNAs in cancers of human and model organisms. Genomics Proteomics Bioinformatics. 20:446–454. 2022. View Article : Google Scholar : PubMed/NCBI
25	Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, et al: MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 286:36677–36685. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lin CJF, Gong HY, Tseng HC, Wang WL and Wu JL: miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 375:315–320. 2008. View Article : Google Scholar : PubMed/NCBI
27	Nakao K, Miyaaki H and Ichikawa T: Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
28	Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Liu H, Ding M, Yang Y, Li L, et al: MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis. 3:e972014. View Article : Google Scholar : PubMed/NCBI
29	Wang K, Jiang X, Jiang Y, Liu J, Du Y, Zhang Z, Li Y, Zhao X, Li J and Zhang R: EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A. J Exp Clin Cancer Res. 42:3202023. View Article : Google Scholar : PubMed/NCBI
30	Nurse P, Masui Y and Hartwell L: Understanding the cell cycle. Nat Med. 4:1103–1106. 1998. View Article : Google Scholar : PubMed/NCBI
31	Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature. 432:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
32	Yu J, Wang Z and Wang Y: BrdU incorporation assay to analyze the entry into S phase. Cell-Cycle Synchronization: Methods and Protocols. Wang Z: Springer US; New York, NY: pp. 209–226. 2022, View Article : Google Scholar
33	Yu F, Wang Z, Wang X, Wang S, Li X, Huang Q and Lin JH: MicroRNA-885-5p promotes osteosarcoma proliferation and migration by downregulation of cell division cycle protein 73 homolog expression. Oncol Lett. 17:1565–1572. 2019.PubMed/NCBI
34	Zu Y, Wang Q and Wang H: Identification of miR-885-5p as a tumor biomarker: Regulation of cellular function in cervical cancer. Gynecol Obstet Invest. 86:525–532. 2021. View Article : Google Scholar : PubMed/NCBI
35	Wang K: Serum miR-885-5p can be used as a marker for efficacy prediction and prognosis of advanced liver cancer. Cell Mol Biol (Noisy-le-grand). 66:135–141. 2020. View Article : Google Scholar : PubMed/NCBI
36	Liu S, Deng X and Zhang J: Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma. Mol Med Rep. 20:5075–5083. 2019.PubMed/NCBI
37	Lam CSC, Ng L, Chow AKM, Wan TMH, Yau S, Cheng NSM, Wong SKM, Man JHW, Lo OSH, Foo DCC, et al: Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer. Oncotarget. 8:26858–26870. 2017. View Article : Google Scholar : PubMed/NCBI
38	Li S, Sun MY and Su X: MiR-885-5p promotes gastric cancer proliferation and invasion through regulating YPEL1. Eur Rev Med Pharmacol Sci. 23:7913–799. 2019.PubMed/NCBI
39	Liu Y, Bao Z, Tian W and Huang G: miR-885-5p suppresses osteosarcoma proliferation, migration and invasion through regulation of β-catenin. Oncol Lett. 17:1996–2004. 2019.PubMed/NCBI
40	Lixin S, Wei S, Haibin S, Qingfu L and Tiemin P: miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Mol Carcinog. 59:1371–1381. 2020. View Article : Google Scholar : PubMed/NCBI
41	Suzuki HI, Katsura A, Matsuyama H and Miyazono K: MicroRNA regulons in tumor microenvironment. Oncogene. 34:3085–3094. 2015. View Article : Google Scholar
42	Marusyk A, Almendro V and Polyak K: Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer. 12:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
43	Zhang Z, Yin J, Yang J, Shen W, Zhang C, Mou W, Luo J, Yan H, Sun P, Luo Y, et al: miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway. Oncotarget. 7:75038–75051. 2016. View Article : Google Scholar : PubMed/NCBI
44	Zou S, Rao Y and Chen W: miR-885-5p plays an accomplice role in liver cancer by instigating TIGAR expression via targeting its promoter. Biotechnol Appl Biochem. 66:763–771. 2019. View Article : Google Scholar : PubMed/NCBI
45	Xu F, Yan JJ, Gan Y, Chang Y, Wang HL, He XX and Zhao Q: miR-885-5p negatively regulates warburg effect by silencing hexokinase 2 in liver cancer. Mol Ther Nucleic Acids. 18:308–319. 2019. View Article : Google Scholar : PubMed/NCBI
46	Knowles BB, Howe CC and Aden DP: Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 209:497–499. 1980. View Article : Google Scholar : PubMed/NCBI
47	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
48	Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sánchez P, Nguyen CB, et al: Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 66:1286–1296. 2017. View Article : Google Scholar
49	Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L and Chen BL: CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics. 10:10619–10633. 2020. View Article : Google Scholar : PubMed/NCBI
50	Naz S, Sowers A, Choudhuri R, Wissler M, Gamson J, Mathias A, Cook JA and Mitchell JB: Abemaciclib, a selective CDK4/6 inhibitor, enhances the radiosensitivity of non-small cell lung cancer in vitro and in vivo. Clin Cancer Res. 24:3994–4005. 2018. View Article : Google Scholar : PubMed/NCBI
51	Huang J, Zheng L, Sun Z and Li J: CDK4/6 inhibitor resistance mechanisms and treatment strategies (review). Int J Mol Med. 50:1282022. View Article : Google Scholar : PubMed/NCBI
52	Cornell L, Wander SA, Visal T, Wagle N and Shapiro GI: MicroRNA-mediated suppression of the TGF-β pathway confers transmissible and reversible CDK4/6 inhibitor resistance. Cell Rep. 26:2667–2680.e7. 2019. View Article : Google Scholar
53	Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, Baselga J, Rosen N and Chandarlapaty S: Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 36:2255–2264. 2017. View Article : Google Scholar :
54	Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed TA, Karoulia Z, Adamopoulos C, Wang H, Wang L, et al: Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nat Cancer. 2:429–443. 2021. View Article : Google Scholar : PubMed/NCBI
55	Dai X and Tan C: Combination of microRNA therapeutics with small-molecule anticancer drugs: Mechanism of action and co-delivery nanocarriers. Adv Drug Deliv Rev. 81:184–197. 2015. View Article : Google Scholar
56	Si W, Shen J, Du C, Chen D, Gu X, Li C, Yao M, Pan J, Cheng J, Jiang D, et al: A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance. Cell Death Differ. 25:406–420. 2018. View Article : Google Scholar :
57	Lu C, Shan Z, Li C and Yang L: MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 86:450–456. 2017. View Article : Google Scholar
58	Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T and Li J: MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Cell Signal. 25:2693–2701. 2013. View Article : Google Scholar : PubMed/NCBI